We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19 TORONTO, Canada -- April 18, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, Canada -- April 12, 2022 -- InvestorsHub NewsWire -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Expected to seek DSMB approval to proceed with EUA application to the FDA in...
HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive...
Β Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation Β TORONTO, February 15, 2022 -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 701 subjects dosed to date Initiating enrollment activities in Turkey as part of its...
Β Revive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsΒ IRB approval to initiate Phase 2 study for methamphetamine abuse disordersΒ Advancing psilocybin oral thin film...
Β Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19Β Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment...
Β Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta VariantΒ TORONTO, November 16, 2021 -- InvestorsHub NewsWire -- Revive...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.001 | 13.3333333333 | 0.0075 | 0.0098 | 0.0065 | 172195 | 0.00753807 | CS |
4 | 0.0024 | 39.3442622951 | 0.0061 | 0.012 | 0.006 | 511313 | 0.00804384 | CS |
12 | 0 | 0 | 0.0085 | 0.012 | 0.0055 | 476590 | 0.0070592 | CS |
26 | -0.0065 | -43.3333333333 | 0.015 | 0.019 | 0.0055 | 362693 | 0.0086665 | CS |
52 | -0.0127 | -59.9056603774 | 0.0212 | 0.036 | 0.0055 | 350917 | 0.01557311 | CS |
156 | -0.4284 | -98.0544747082 | 0.4369 | 0.440661 | 0.0055 | 438512 | 0.12221766 | CS |
260 | -0.0198 | -69.964664311 | 0.0283 | 0.72 | 0.0055 | 1058533 | 0.27806511 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions